메뉴 건너뛰기




Volumn , Issue 40, 2013, Pages 12-17

Formulation technology enables the delivery of hiv medicines

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; COBICISTAT; EFAVIRENZ; ETRAVIRINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE;

EID: 84905647237     PISSN: 17414911     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article
Times cited : (5)

References (42)
  • 1
    • 84884526776 scopus 로고    scopus 로고
    • The current state of HIV therapy
    • Benzer JA, et al. The current state of HIV therapy. Formulary 2013;48:213-223.
    • (2013) Formulary , vol.48 , pp. 213-223
    • Benzer, J.A.1
  • 2
    • 84880333268 scopus 로고    scopus 로고
    • Advances in antiretroviral therapy
    • Arribas JR, Eron J. Advances in antiretroviral therapy. Curr Opin HIV AIDS 2013;8:1-9.
    • (2013) Curr Opin HIV AIDS , vol.8 , pp. 1-9
    • Arribas, J.R.1    Eron, J.2
  • 3
    • 84876731120 scopus 로고    scopus 로고
    • Anti-hiv drug development: Structural features and limitations of present day drugs and future challenges in the successful HIV/AIDS treatment
    • Kumari G, Singh RK. Anti-HIV drug development: Structural features and limitations of present day drugs and future challenges in the successful HIV/AIDS treatment. Curr Pharmaceut Design 2013;19:1767-1783.
    • (2013) Curr Pharmaceut Design , vol.19 , pp. 1767-1783
    • Kumari, G.1    Singh, R.K.2
  • 4
    • 0037624182 scopus 로고    scopus 로고
    • Twenty years of therapy for HIV-1 infection
    • Pomerantz RJ, Horn DL. Twenty years of therapy for HIV-1 infection. Nat Med 2003;9:867-873.
    • (2003) Nat Med , vol.9 , pp. 867-873
    • Pomerantz, R.J.1    Horn, D.L.2
  • 5
    • 36749088862 scopus 로고    scopus 로고
    • Hiv drug development: The next 25 years
    • Flexner C. HIV drug development: The next 25 years. Nat Rev Drug Discov 2007;6:959-966.
    • (2007) Nat Rev Drug Discov , vol.6 , pp. 959-966
    • Flexner, C.1
  • 6
    • 84905646069 scopus 로고    scopus 로고
    • Compressed tablet formulation
    • Batra U, et al. Compressed tablet formulation. US Patent US7707294; 2006.
    • (2006) US Patent US7707294
    • Batra, U.1
  • 7
    • 36849020049 scopus 로고    scopus 로고
    • Investigation of human pharmacoscintigraphy behaviour of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (efavirenz
    • Gao JZ, et al. Investigation of human pharmacoscintigraphy behaviour of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (efavirenz). J Pharm Sci 2007;96:2970-2977.
    • (2007) J Pharm Sci , vol.96 , pp. 2970-2977
    • Gao, J.Z.1
  • 9
    • 84905664418 scopus 로고    scopus 로고
    • Development of Atripla® a fixed dose combination tablet of three drugs: Efavirenz emtricitabine and tenofovir disoproxil fumarate
    • Presented at
    • Hussain MA, et al. Development of Atripla® , a fixed dose combination tablet of three drugs: Efavirenz, emtricitabine, and tenofovir disoproxil fumarate. Presented at AAPS Annual Meeting, New Orleans, LA, USA; 2010.
    • (2010) AAPS Annual Meeting New Orleans la USA
    • Hussain, M.A.1
  • 10
    • 84905646070 scopus 로고    scopus 로고
    • Dry granulated composition comprising emtricitabine and tenofovir disoproxil fumarate
    • Dahl TC et al. Dry granulated composition comprising emtricitabine and tenofovir disoproxil fumarate European patent specification EP1890681 2009
    • (2009) European Patent Specification EP1890681
    • Dahl, T.C.1
  • 11
    • 77954618054 scopus 로고    scopus 로고
    • One-pill once-A-day haart: A simplification strategy that improves adherence and quality of life in hiv-infected patients
    • Airoldi M et al. One-pill once-A-day haart: A simplification strategy that improves adherence and quality of life in hiv-infected patients. Patient Prefer Adherence, 2010, 4 115-125
    • (2010) Patient Prefer Adherence , vol.4 , pp. 115-125
    • Airoldi, M.1
  • 12
    • 78650039081 scopus 로고    scopus 로고
    • Physicochemical properties of the amorphous drug, cast films, and spray dried powders to predict formulation probability of success for solid dispersions: Etravirine
    • Weuts I et al. Physicochemical properties of the amorphous drug, cast films, and spray dried powders to predict formulation probability of success for solid dispersions: Etravirine.J Pharm Sci 2011 100 260-274
    • (2011) J Pharm Sci , vol.100 , pp. 260-274
    • Weuts, I.1
  • 13
    • 73949154387 scopus 로고    scopus 로고
    • An investigation into the crystallisation behaviour of an amorphous cryomilled pharmaceutical material above and below the glass transition temperature
    • Qi S et al. An investigation into the crystallisation behaviour of an amorphous cryomilled pharmaceutical material above and below the glass transition temperature. J Pharm Sci. 2010. 99.196-208
    • (2010) J Pharm Sci , vol.99 , pp. 196-208
    • Qi, S.1
  • 14
    • 61349103126 scopus 로고    scopus 로고
    • Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers
    • Kakuda TN et al. Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers. HIV Med, 2009, 10, 173-181
    • (2009) HIV Med , vol.10 , pp. 173-181
    • Kakuda, T.N.1
  • 16
    • 84905655133 scopus 로고    scopus 로고
    • Beads having a core coated with an antifungal and a polymer
    • Gilis P.M.V. et al. Beads having a core coated with an antifungal and a polymer,US patent 5633015, 1997
    • (1997) US Patent 5633015
    • Gilis, P.M.V.1
  • 17
    • 84905673466 scopus 로고    scopus 로고
    • HIV replication inhibiting pyrimidines
    • De Corte B et al.HIV replication inhibiting pyrimidines, US patent 7037197, 2006
    • (2006) US Patent 7037197
    • De Corte, B.1
  • 18
    • 84905673467 scopus 로고    scopus 로고
    • Process for preparing spray dried formulation of TMC125
    • Kiekens FRI et al. Process for preparing spray dried formulation of TMC125. US patent application 2009/0197903, 2009
    • (2009) US Patent Application 2009/0197903
    • Fri, K.1
  • 19
    • 49949104484 scopus 로고    scopus 로고
    • Single and multipledose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients
    • Kakuda TN et al. Single and multipledose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients. Antiviral Ther, 2008, 1,655-661
    • (2008) Antiviral Ther , vol.1 , pp. 655-661
    • Kakuda, T.N.1
  • 20
    • 84886012661 scopus 로고    scopus 로고
    • Discovery and development of HIV-1entry inhibitors that target gp120
    • In (Kazmierski WM, Ed Hoboken, NJ, USA Wiley
    • Kadow JF, et al. Discovery and development of HIV-1entry inhibitors that target gp120. In: Antiviral Drugs: From Basic Discovery Through to Clinical Trials (Kazmierski WM, Ed). Hoboken, NJ, USA: Wiley; 2011.
    • (2011) Antiviral Drugs: From Basic Discovery Through to Clinical Trials
    • Kadow, J.F.1
  • 22
    • 84905646068 scopus 로고    scopus 로고
    • Stable pharmaceutical composition for optimized delivery of an HIV attachment inhibitor
    • Brown JR et al. Stable pharmaceutical composition for optimized delivery of an HIV attachment inhibitor. European patent specification EP 2323633, 2012
    • (2012) European Patent Specification EP 2323633
    • Brown, J.R.1
  • 23
    • 84877927926 scopus 로고    scopus 로고
    • Compartmental absorption modeling and site of absorption studies to determine feasibility of an extendedrelease formulation of an HIV-1 attachment inhibitor phosphate ester prodrug
    • Brown J et al. Compartmental absorption modeling and site of absorption studies to determine feasibility of an extendedrelease formulation of an HIV-1 attachment inhibitor phosphate ester prodrug. J Pharm Sci.2013. 102. 1742-1751
    • (2013) J Pharm Sci , vol.102 , pp. 1742-1751
    • Brown, J.1
  • 24
    • 84979509546 scopus 로고    scopus 로고
    • Investigation into the potential for prodrug hydrolysis within a hydrated HPMC matrix
    • Edinburgh, UK
    • Hanley S, et al. Investigation into the potential for prodrug hydrolysis within a hydrated HPMC matrix. Presented at APS PharmSci Conference, Edinburgh, UK; 2013.
    • (2013) Presented at APS PharmSci Conference
    • Hanley, S.1
  • 25
    • 84868545732 scopus 로고    scopus 로고
    • The use of amorphous solid dispersions: A formulation strategy to overcome poor solubility and dissolution rate
    • Van den Mooter G. The use of amorphous solid dispersions: A formulation strategy to overcome poor solubility and dissolution rate. Drug Discov Today: Technologies 2012;9:e79-e85.
    • (2012) Drug Discov Today: Technologies , vol.9 , pp. 79-85
    • Van Den Mooter, G.1
  • 26
    • 84884140474 scopus 로고    scopus 로고
    • Melt extrusion with poorly soluble drugs
    • Shah S, et al. Melt extrusion with poorly soluble drugs. Int J Pharm 2013;453:233-252.
    • (2013) Int J Pharm , vol.453 , pp. 233-252
    • Shah, S.1
  • 27
    • 0014982253 scopus 로고
    • Hot extruded dosage forms. Part 1: Technology and dissolution of polymeric matrices
    • El-Agakey MA, et al. Hot extruded dosage forms. Part 1: Technology and dissolution of polymeric matrices. Pharm Acta Helv 1971;46:31-52.
    • (1971) Pharm Acta Helv , vol.46 , pp. 31-52
    • El-Agakey, M.A.1
  • 28
    • 0031869733 scopus 로고    scopus 로고
    • Solid dispersions by an integrated melt extrusion system
    • Breitenbach J et al. Solid dispersions by an integrated melt extrusion system. Proc Intl Symp Control Rel Bioactive Mater. 1998. 25. 804-805
    • (1998) Proc Intl Symp Control Rel Bioactive Mater , vol.25 , pp. 804-805
    • Breitenbach, J.1
  • 29
    • 84875904527 scopus 로고    scopus 로고
    • EMA 27 April Downloaded on 9 October 2013 from
    • EMA. Kaletra, Scientific Discussion, 27 April 2006. Downloaded on 9 October 2013 from www.ema.europa.eu/ema/index.jsp?curl= pages/medicines/human/ medicines/00036 8/human-med-000867.jsp&mid=WC0b01 ac058001d124
    • (2006) Kaletra and Scientific Discussion
  • 30
    • 33745929028 scopus 로고    scopus 로고
    • Melt extrusion can bring new benefits to HIV therapy: The example of Kaletra tablets
    • Breitenbach J. Melt extrusion can bring new benefits to HIV therapy: The example of Kaletra tablets. Am J Drug Deliv. 2006. 4. 61-64
    • (2006) Am J Drug Deliv , vol.4 , pp. 61-64
    • Breitenbach, J.1
  • 31
    • 34147176581 scopus 로고    scopus 로고
    • The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect
    • Klein CE et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr. 2007. 44. 401-410
    • (2007) J Acquir Immune Defic Syndr , vol.44 , pp. 401-410
    • Klein, C.E.1
  • 32
    • 84905664415 scopus 로고    scopus 로고
    • EMA 21 March 2013 Downloaded on 18 October 2013 from
    • EMA. Committee for Medicines for Human Use, Assessment Report: Stribild, 21 March 2013. Downloaded on 18 October 2013 from www.ema.europa.eu/ema/index. jsp?curl= pages/medicines/human/medicines/00257 4/human-med-001654.jsp&mid= WC0b01 ac058001d124
    • Committee for Medicines for Human Use, Assessment Report: Stribild
  • 33
    • 84905664416 scopus 로고    scopus 로고
    • Use of solid carrier particles to improve the processability of a pharmaceutical agent
    • Kozlara JM et al.Use of solid carrier particles to improve the processability of a pharmaceutical agent. US patent application US 2009/0324729. 2009
    • (2009) US Patent Application US 2009/0324729
    • Kozlara, J.M.1
  • 34
    • 0033384441 scopus 로고    scopus 로고
    • Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers
    • Lamson MJ, et al. Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharm Drug Dispos 1999;20:285-291.
    • (1999) Biopharm Drug Dispos , vol.20 , pp. 285-291
    • Lamson, M.J.1
  • 35
    • 33846272175 scopus 로고    scopus 로고
    • Once-daily nevirapine dosing: A pharmacokinetics, efficacy and safety review
    • Cooper CL van Heeswijk RP. Once-daily nevirapine dosing: A pharmacokinetics, efficacy and safety review. HIV Med. 2007. 8. 1-7
    • (2007) HIV Med , vol.8 , pp. 1-7
    • Cooper, C.L.1    Van Heeswijk, R.P.2
  • 36
    • 84865796028 scopus 로고    scopus 로고
    • Predicting feasibility and characterizing performance of extendedrelease formulations using physiologically based pharmacokinetic modelling
    • Brown J et al.Predicting feasibility and characterizing performance of extendedrelease formulations using physiologically based pharmacokinetic modeling. Therapeut Deliv. 2012.3. 1047-1059
    • (2012) Therapeut Deliv , vol.3 , pp. 1047-1059
    • Brown, J.1
  • 37
    • 71449125747 scopus 로고    scopus 로고
    • Assessment of nevirapine bioavailability from targeted sites in the human gastrointestinal tract
    • Macha S et al. Assessment of nevirapine bioavailability from targeted sites in the human gastrointestinal tract. J Clin Pharmacol.2009. 49.1417-1425
    • (2009) J Clin Pharmacol , vol.49 , pp. 1417-1425
    • Macha, S.1
  • 38
    • 79959756040 scopus 로고    scopus 로고
    • Evaluation of human regional bioavailability to assess whether modified release development is feasible
    • Presented at San Diego CA, USA
    • Connor A, et al. Evaluation of human regional bioavailability to assess whether modified release development is feasible. Presented at AAPS Annual Meeting, San Diego CA, USA; 2007.
    • (2007) AAPS Annual Meeting
    • Connor, A.1
  • 39
    • 84905645991 scopus 로고    scopus 로고
    • Extended release formulation of nevirapine
    • Cappola ML et al. Extended release formulation of nevirapine. US patent US 8460704. 2013
    • (2013) US Patent US 8460704
    • Cappola, M.L.1
  • 40
    • 73349133044 scopus 로고    scopus 로고
    • Vitro-in vivo correlation for nevirapine extended release tablets
    • Macha S, et al. In vitro-in vivo correlation for nevirapine extended release tablets. Biopharm Drug Dispos 2009;30:542-550.
    • (2009) Biopharm Drug Dispos , vol.30 , pp. 542-550
    • Macha, S.1
  • 41
    • 80053006457 scopus 로고    scopus 로고
    • Bioavailability of extended-release nevirapine 400 and 30 mg in HIV-1: A multicenter, open-label study
    • Battegay M et al. Bioavailability of extended-release nevirapine 400 and 30 mg in HIV-1: A multicenter, open-label study. Clin Ther. 2011. 33. 1308-1320
    • (2011) Clin Ther , vol.33 , pp. 1308-1320
    • Battegay, M.1
  • 42
    • 0001474469 scopus 로고    scopus 로고
    • Nevirapine induces both cyp3a4 and cyp2b6 metabolic pathways
    • Lamson M, et al. Nevirapine induces both CYP3A4 and CYP2B6 metabolic pathways. Clin Pharm Ther 1999;65:137.
    • (1999) Clin Pharm Ther , vol.65 , pp. 137
    • Lamson, M.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.